MERGERS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

After last month’s flurry of transactions, business calmed down as it often does during the start of summer. Here are the key deals and trends from mid-June through the third week of … [Read more...]

ACQUISITIONS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

Mid-May to mid-June was the busiest period of the year for diagnostic deal making in terms of both volume and magnitude. Here is a look at the highlights. M&A Dollar value-wise, the biggest lab … [Read more...]

DISTRIBUTION AGREEMENTS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

The pace of deal making has picked up a bit, but deal volume remains relatively low on both the M&A and strategic alliance fronts. As usual, smaller molecular and genomics firms are supplying … [Read more...]

GENOMICS

Market Trends: Genetic Testing Becoming a Hot New Employee Benefit

While its clinical utility remains subject to debate, genetic testing has proven its value as an employment recruitment tool, especially on the West Coast where technology firms are leveraging its … [Read more...]

DISTRIBUTION AGREEMENTS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

While M&A activity in the wider healthcare industry is heating up deal making in the diagnostics space remains relatively light, not so much in terms of volume but in size, at least compared to … [Read more...]

PARTNERSHIPS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

The strategic slowdown in the diagnostics sector continues. Late February to March was relatively light in both deal volume and value, especially compared to the same period in 2017. As usual, the … [Read more...]

MARKETING

Theranos & Its CEO Settle Stock Fraud Charges with SEC

Seven years ago, Theranos was a $9 billion dynamo seemingly on the precipice of blowing the blood testing market wide open. Today, the company and its CEO and founder, Elizabeth Holmes, are a … [Read more...]

DISTRIBUTION AGREEMENTS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

Based on the early returns, the market analysts that predicted 2018 would see a slowdown in strategic Dx deal making appear to be right. But while deal volume was low on both the M&A and alliance … [Read more...]

MARKETING

Theranos & Its CEO Settle Stock Fraud Charges with SEC

CMS; The Arizona Attorney General; Walgreen's; Its own shareholders. And now Theranos has a new legal adversary: the US Securities Exchange Commission which has charged Theranos and its founder … [Read more...]

INTELLECTUAL PROPERTY

Happy Endings: Guardant & Foundation Make Sweet Lemonade Out of False Advertising Lemons

In June 2017, Guardant Health sued Foundation Medicine for making false statements about the Guardant360 test in its advertisements for the FoundationACT liquid biopsy genomic profiling test. … [Read more...]


(-0000g2)